[go: up one dir, main page]

MX2020007844A - Camara de biodifusion. - Google Patents

Camara de biodifusion.

Info

Publication number
MX2020007844A
MX2020007844A MX2020007844A MX2020007844A MX2020007844A MX 2020007844 A MX2020007844 A MX 2020007844A MX 2020007844 A MX2020007844 A MX 2020007844A MX 2020007844 A MX2020007844 A MX 2020007844A MX 2020007844 A MX2020007844 A MX 2020007844A
Authority
MX
Mexico
Prior art keywords
semi
permeable membrane
biodiffusion chamber
chamber
permeable
Prior art date
Application number
MX2020007844A
Other languages
English (en)
Inventor
Brendan Laurenzi
Douglas Craig Hooper
David Andrews
William Hitchings
Dominic Ventura
Kara Pigott
Original Assignee
Univ Jefferson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Jefferson filed Critical Univ Jefferson
Publication of MX2020007844A publication Critical patent/MX2020007844A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0069—Devices for implanting pellets, e.g. markers or solid medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
    • A61M39/02—Access sites
    • A61M39/0208—Subcutaneous access sites for injecting or removing fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
    • A61M5/14276—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
    • A61M39/02—Access sites
    • A61M2039/0205—Access sites for injecting media
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
    • A61M39/02—Access sites
    • A61M39/0208—Subcutaneous access sites for injecting or removing fluids
    • A61M2039/0223—Subcutaneous access sites for injecting or removing fluids having means for anchoring the subcutaneous access site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2206/00—Characteristics of a physical parameter; associated device therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Prostheses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se provee una cámara de biodifusión para realizar la vacunación de células autólogas. La cámara de biodifusión está adaptada para insertarse en un sujeto y extraerse del mismo. En algunas modalidades, la cámara de biodifusión comprende (i) un cuerpo de la cámara que define una cavidad hueca e incluye una primera superficie y una segunda superficie, (ii) una primera membrana semipermeable acoplada a la primera superficie, (iii) una segunda membrana semipermeable acoplada a la segunda superficie, y (iv) un elemento y/o característica adaptada para retirar la cámara de biodifusión del sujeto. La primera membrana semipermeable y la segunda membrana semipermeable son permeables a fluidos y factores solubles, pero no son permeables a células. En algunas modalidades, la composición que comprende una cantidad terapéuticamente efectiva de un oligodesoxinucleótido antisentido se inserta en la cámara de biodifusión y se deja difundir hacia fuera de la cámara de biodifusión y hacia dentro del sujeto a través de al menos una de la primera membrana semipermeable o la segunda membrana semipermeable.
MX2020007844A 2018-01-24 2019-01-24 Camara de biodifusion. MX2020007844A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862621295P 2018-01-24 2018-01-24
PCT/US2019/014961 WO2019147817A1 (en) 2018-01-24 2019-01-24 Biodiffusion chamber

Publications (1)

Publication Number Publication Date
MX2020007844A true MX2020007844A (es) 2021-01-20

Family

ID=67394768

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007844A MX2020007844A (es) 2018-01-24 2019-01-24 Camara de biodifusion.

Country Status (10)

Country Link
US (2) US20210052875A1 (es)
EP (1) EP3743519A4 (es)
JP (1) JP7406213B2 (es)
KR (2) KR20250067183A (es)
CN (1) CN112204140A (es)
AU (2) AU2019212356A1 (es)
BR (1) BR112020015028A2 (es)
CA (1) CA3089583A1 (es)
MX (1) MX2020007844A (es)
WO (1) WO2019147817A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10206942B2 (en) 2015-04-10 2019-02-19 Thomas Jefferson University Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory M2 monocytes
CA3054662A1 (en) * 2017-03-09 2018-09-13 Thomas Jefferson University Methods and compositions for treating cancers using antisense
US20220370773A1 (en) * 2019-09-19 2022-11-24 Thomas Jefferson University Apparatus and methods for biodiffusion chamber storage
CN111362258A (zh) * 2020-02-12 2020-07-03 浙江大学 一种蜂蜡作支撑层的石墨烯薄膜转移方法
CN113189638B (zh) * 2021-04-21 2024-04-05 中国科学院国家空间科学中心 一种基于粒子径迹成像云室的粒子运动轨迹成像装置

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3831583A (en) * 1971-03-05 1974-08-27 Univ California Implantable bulb for inflation of surgical implements
US5167638A (en) * 1989-10-27 1992-12-01 C. R. Bard, Inc. Subcutaneous multiple-access port
US5834005A (en) * 1992-02-24 1998-11-10 Encelle, Inc. Bioartificial devices and cellular matrices therefor
US5714170A (en) * 1994-11-16 1998-02-03 Thomas Jefferson University Method of inducing resistance to tumor growth
US6541036B1 (en) * 1997-05-29 2003-04-01 Thomas Jefferson University Treatment of tumors with oligonucleotides directed to insulin-like growth factor-I receptors (IGF-IR)
IL134009A (en) * 2000-01-12 2011-07-31 Bo2 Technologies Ltd Transplant device
US7037335B2 (en) * 2002-11-19 2006-05-02 Eagle Vision, Inc. Bulbous scleral implants for the treatment of eye disorders such as presbyopia and glaucoma
US7361168B2 (en) * 2004-04-21 2008-04-22 Acclarent, Inc. Implantable device and methods for delivering drugs and other substances to treat sinusitis and other disorders
CA2726861C (en) * 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US9446168B2 (en) * 2010-06-07 2016-09-20 Beta-O2 Technologies Ltd. Multiple-layer immune barrier for donor cells
FI123146B (fi) * 2009-10-01 2012-11-30 Bayer Schering Pharma Oy Kohdunsisäinen järjestelmä
WO2012041320A1 (en) * 2010-09-27 2012-04-05 Nsgene A/S Implantable cell device with supportive and radial diffusive scaffolding
CN105142570B (zh) * 2013-04-24 2018-06-22 雀巢产品技术援助有限公司 包封装置
MX384445B (es) * 2013-09-24 2025-03-14 Giner Inc Sistema para tratamiento con gas de un implante de células.
ES2613521T3 (es) * 2014-01-03 2017-05-24 Koninklijke Philips N.V. Evaluación de la actividad de la ruta de señalización celular PI3K utilizando una modelación matemática de expresión de genes diana
US9872674B2 (en) * 2014-05-07 2018-01-23 Boehringer Laboratories Inc. Entrapment and containment system for use with a morcellator and method of entrapping and containing material produced during morcellation procedure
US10206942B2 (en) 2015-04-10 2019-02-19 Thomas Jefferson University Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory M2 monocytes
JP7080642B2 (ja) * 2015-04-23 2022-06-06 アプライド メディカル リソーシーズ コーポレイション 組織取り出しシステムおよび方法
EA038277B1 (ru) 2015-10-14 2021-08-04 Байо-Пат Холдингз, Инк. P-этокси нуклеиновые кислоты для липосомальной лекарственной формы
CA3054662A1 (en) 2017-03-09 2018-09-13 Thomas Jefferson University Methods and compositions for treating cancers using antisense
JP2022512896A (ja) * 2018-11-02 2022-02-07 トーマス・ジェファーソン・ユニバーシティ アンチセンスを使用した肝細胞癌治療用の方法および組成物
US20220370773A1 (en) * 2019-09-19 2022-11-24 Thomas Jefferson University Apparatus and methods for biodiffusion chamber storage
BR112022018478A2 (pt) * 2020-03-18 2023-01-24 Takeda Pharmaceuticals Co Dispositivo de câmara celular implantável e usos do mesmo
EP4132462A1 (en) * 2020-04-09 2023-02-15 Defymed Membranes for medical devices

Also Published As

Publication number Publication date
JP2021511832A (ja) 2021-05-13
KR102802097B1 (ko) 2025-04-29
AU2019212356A1 (en) 2020-08-13
KR20200113245A (ko) 2020-10-06
EP3743519A4 (en) 2022-02-23
CN112204140A (zh) 2021-01-08
CA3089583A1 (en) 2019-08-01
WO2019147817A1 (en) 2019-08-01
US20210052875A1 (en) 2021-02-25
KR20250067183A (ko) 2025-05-14
BR112020015028A2 (pt) 2020-12-29
AU2025203888A1 (en) 2025-06-19
US20250276166A1 (en) 2025-09-04
JP7406213B2 (ja) 2023-12-27
EP3743519A1 (en) 2020-12-02

Similar Documents

Publication Publication Date Title
MX2020007844A (es) Camara de biodifusion.
IL277025B2 (en) Methods of enhancing stem cell differentiation into beta cells
CL2010000710A1 (es) Uso de una canula para la irradiacion de un objetivo en un ojo,en que la canula esta configurada ser insertada en un espacio potencial debajo de la capsula de tenon del ojo, la insercion de la canula permite la observacion a traves de la pupila, puede ser ajustada y permite la irradiacion del objetivo con rbs.
WO2010149597A3 (en) 3D CULTURING SYSTEMS FOR GROWTH AND DIFFERENTIATION OF HUMAN PLURIPOTENT STEM (hPS) CELLS
DK2257496T3 (da) System og fremgangsmåde til dyrkning af nanorør ved ionimplantering under anvendelse af en katalytisk transmembran
WO2012006072A3 (en) Air impedance electrospinning for controlled porosity
PH12018500371A1 (en) Clinical formulations
JP2012506430A5 (es)
NZ609731A (en) Compositions of adult organ stem cells and uses thereof
WO2010111522A3 (en) Mesenchymal stem cells producing inhibitory rna for disease modification
WO2011018798A3 (en) Morpholino-based antisense agent
EP4303317A3 (en) Removing and reinserting protein nanopores in a membrane using osmotic imbalance
BR112013005756A2 (pt) use of anti third party central memory t cells for anti-leukemia/lymphoma treatment
CO2021018034A2 (es) Oligonucleótidos gapmer modificados y métodos de uso
Zhao et al. Fluctuating expression of microRNAs in adenovirus infected cells
EP4595951A3 (en) Pdx1 pancreatic endoderm cells in cell delivery devices
MX2017008659A (es) Reactor biopelicula de membrana aireada.
MX2022002639A (es) Sistema y metodo para limpiar un filtro de sangre en forma eficiente.
WO2007103379A3 (en) Method for endothelial cell extraction from adipose tissues
AR079710A1 (es) Proceso para el cultivo de celulas adherentes
MX2021007674A (es) Un indicador de tratamiento, un metodo de produccion del mismo y un metodo de uso del mismo.
MX2018007986A (es) Terapia genica para epidermolisis ampollosa distrofica recesiva con queratinocitos autologos geneticamente corregidos.
MX2012014619A (es) Filtro de flujo para separar sangre en plasma y constituyentes celulares.
RU2018139710A (ru) Дифференцировка плюрипотентных стволовых клеток в клетки кишечной энтодермы средней кишки
Priola Cell biology of prion infection